Table 24. Survival of Patients with CRC PC Treated by CRS and HIPEC and/or EPIC and/or SC: Summary of 76 Researches.
| Author/ Years/ Country | 1-yr SR (%) | 2-yr SR (%) | 3-yr SR (%) | 4-yr SR (%) | 5-yr SR (%) | Mortality Rate (%) |
Morbidity Rate (%) |
Median OS (mo) |
OS 95% CI (mo) |
PFS(95% CI) (mo) | DFS/RFS (95% CI) (mo) |
Follow-up times (range) (mo) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HIPEC single arm studies | ||||||||||||
| Rodt/ 2013/ Denmark [75] | ≈52 | ≈36 | ≈12 | 0 | 0 | 0 | 9.4 (all) | 12.7 | 4.0-21.4 | NR | NR | 13 (1-44) |
| Shen/ 2004/ America [20] | NR | NR | 25 | NR | 17 | 12 | 30 | 16 | 10-26 | 7 (3-31) | NR | 15 |
| Shen/ 2008/ America [76] | 91 | ≈60 | 48 | ≈32 | 26 | 5.5 | 41.8 | 34 | 23-45 | NR | NR | 86 |
| Simkens/ 2015/ Netherlands [102] | NR | NR | 42 | NR | NR | 3 | 24.8 | 27 | 18.8-35.3 | NR | 1-yr: 35% | 22.9 (0.4-75.3) |
| Swellengrebel/ 2009/ Netherlands [77] |
NR | NR | NR | NR | NR | NR | NR | 25.6 | 20.9-29.4 | 13.6 (11.2-16.4) | NR | NR |
| Tabrizian/ 2014/ America [78] | 74.0 | ≈47 | 89.4 | NA | NA | NR | NR | NR | NR | NR | 12.4±1.8 (RFS) 1-,3-yr, 46.9%, 73.9% |
15.7±1.2 |
| Teo/ 2013/ Singapore [79] | ≈87 | ≈58 | ≈36 | ≈18 | ≈18 | 0 | 56 (all) | ≈28 | NR | NR | ≈10 | 21 (13.9-31.3) (all) |
| Teo/ 2014/ Singapore [80] | 83.7 | ≈53 | 38.2 | 19.1 | 19.1 | 0 | 40 | 27.1 | 15.3-39.1 | NR | 9.4 (5.5-18.7) 1-,3-,5-yr, 43.8%, 22.3%, 22.3% |
24.7 (0.6-81.8) |
| Ung/ 2013/ Australia [81] | ≈84 (Colon) | ≈63 (Colon) | ≈53 (Colon) | ≈37 (Colon) | 33 (Colon) | NR | NR | 37.1 (Colon) 29.6 (Rectal) |
NR | NR | 12.6 (Colon) 19.0 (Rectal) |
23.3 (1-156) (all) |
| Vaira/ 2010/ Italy [82] |
100 (L-OHP) ≈61 (MMC) |
≈60 (L-OHP) ≈17 (MMC) |
≈18 (L-OHP) ≈9 (MMC) |
≈18 (L-OHP) ≈4 (MMC) |
NA (L-OHP) 0 (MMC) |
2.5 | 55 | 24.6 (L-OHP) 16.6 (MMC) |
NR | NR | NR | NR |
| van Leeuwen / 2008/ Sweden [83] | ≈82 | ≈65 | NA | NA | NA | >1 (all) | 56.3 (all) | NA | NA | NR | 2-yr, 33.5% (all) | 13 (2-37) (all) |
| van Oudheusden/ 2014/ Netherlands [84] |
≈86 | ≈70 | ≈43 | ≈30 | ≈22 | 1.8 | 22.1 | 36.1 | NR | NR | NR | 16.2 (0.13-90) |
| van Oudheusden / 2015/ Netherlands [85] |
≈87 | ≈68 | 44 | ≈38 | ≈27 | NR | 13.5 | 35.1 | NR | NR | NR | 12.7(0.10-90.2) |
| Varban/ 2009/ America [86] | ≈63 | 36.8 | ≈25 | 17.4 | ≈16 | 7.7 | 40.1 | 15.8 | 13.5-20.2 | NR | NR | 13.4 |
| Verwaal/ 2005/ Netherlands [19] | 75 | NR | 28 | NR | 19 | NR | NR | 21.8 | 19.0-25.5 | NR | NR | 46 |
| Votanopoulos/ 2013/ America [87] | ≈63 (Colon) ≈83 (Rectal) |
≈31 (Colon) ≈36 (Rectal) |
25.1 (Colon) 28.2 (Rectal) |
NR | NR | 5.7 (Colon) 0 (Rectal) |
57 (Colon) 46 (Rectal) |
17.3 (Colon) 14.6 (Rectal) |
NR | NR | NR | 88.1 (Colon) 40.1 (Rectal) |
Note: yr: year; SR: survival rate; mo: months; OS: overall survival; PFS: progression-free survival; RFS: recurrence-free survival; DFS: disease-free survival; NA: not achieved; NR: not reported; PMP: pseudomyxoma peritonei; L-OHP: oxaliplatin; MMC: mitomycin; all: all tumors in researches; MVR: multivisceral resection group; NVR: No visceral resection group; APP: appendix; NNT: non-neoadjuvant therapy; NCA: neoadjuvant chemotherapy alone; NCB: neoadjuvant chemotherapy + bevacizumab; AC: adjuvant chemotherapy; NAC: non- adjuvant chemotherapy